Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Fast Becoming World’s Pharmaceutical Formulation Factory

This article was originally published in PharmAsia News

Executive Summary

Zhejiang Huahai Pharmaceutical will cooperate with U.S. firm Enspire and invest $10 million to set up a new overseas company to develop, produce and sell soft capsules. Last July, Huahai gained U.S. FDA tentative approval to launch its anti-AIDS drug nevirapine in the U.S. in 2012, a first for a pharmaceutical company from China. In addition, it is China's only enterprise to receive FDA authorization for its solid pharmaceutical formulation workshop. Experts observe that currently fewer than 10 pharmaceutical firms in China have gained European and American certification. More than 20 companies are in the application stage and may receive licenses over the next two years. China's low-cost advantage attracts outsourcing by pharmaceutical MNCs and the country is poised to be the world's pharmaceutical formulation factory
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel